COCP vs. ONCT, CKPT, TLSA, ANIX, ETON, VSTM, CLRB, CASI, CLSD, and IFRX
Should you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include Oncternal Therapeutics (ONCT), Checkpoint Therapeutics (CKPT), Tiziana Life Sciences (TLSA), Anixa Biosciences (ANIX), Eton Pharmaceuticals (ETON), Verastem (VSTM), Cellectar Biosciences (CLRB), CASI Pharmaceuticals (CASI), Clearside Biomedical (CLSD), and InflaRx (IFRX). These companies are all part of the "pharmaceutical preparations" industry.
Cocrystal Pharma (NASDAQ:COCP) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.
Cocrystal Pharma has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.
Cocrystal Pharma presently has a consensus price target of $10.00, indicating a potential upside of 354.55%. Oncternal Therapeutics has a consensus price target of $28.33, indicating a potential upside of 301.89%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Cocrystal Pharma is more favorable than Oncternal Therapeutics.
6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 16.1% of Oncternal Therapeutics shares are owned by institutional investors. 25.6% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Cocrystal Pharma has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -3,160.73%. Cocrystal Pharma's return on equity of -61.61% beat Oncternal Therapeutics' return on equity.
Oncternal Therapeutics received 9 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 75.86% of users gave Cocrystal Pharma an outperform vote while only 30.39% of users gave Oncternal Therapeutics an outperform vote.
In the previous week, Cocrystal Pharma and Cocrystal Pharma both had 2 articles in the media. Oncternal Therapeutics' average media sentiment score of 0.93 beat Cocrystal Pharma's score of 0.81 indicating that Oncternal Therapeutics is being referred to more favorably in the news media.
Cocrystal Pharma has higher earnings, but lower revenue than Oncternal Therapeutics. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Cocrystal Pharma beats Oncternal Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Cocrystal Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cocrystal Pharma Competitors List
Related Companies and Tools
Free COCP Stock Alerts